Pfizer and Biontech expand study of vaccines for children
The New York Times reports that vaccine studies involving children aged 5-11 will be made more comprehensive in the wake of a request from the FDA.
BY RITZAU FINANS, TRANSLATED BY NIELSINE NIELSEN
Vaccine trials for children aged 5-11 should be more comprehensive. For this reason, studies of the Pfizer-Biontech vaccine and the Moderna vaccine within this group will now be expanded, writes the New York Times.
Already a subscriber?Log in here
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
- Access all locked articles
- Receive our daily newsletters
- Access our app
Get full access for you and your coworkers
Start a free company trial todayRelated articles:
Sweden phases out AstraZeneca's covid-19 vaccine
For subscribers
